Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Cellectis S.A. (NASDAQ:CLLS) have earned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $6.3333.

A number of research analysts have issued reports on CLLS shares. Jefferies Financial Group initiated coverage on Cellectis in a research note on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st. Finally, Clear Str upgraded Cellectis to a “strong-buy” rating in a report on Tuesday, December 23rd.

Institutional Trading of Cellectis

Institutional investors and hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC bought a new stake in Cellectis during the 4th quarter valued at about $34,000. Delaney Dennis R bought a new position in shares of Cellectis in the third quarter worth approximately $68,000. Virtu Financial LLC bought a new position in shares of Cellectis in the third quarter worth approximately $72,000. Acadian Asset Management LLC grew its holdings in shares of Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 26,461 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors.

Cellectis Stock Performance

Cellectis stock opened at $3.42 on Friday. Cellectis has a twelve month low of $1.10 and a twelve month high of $5.48. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.49 and a current ratio of 1.49. The stock’s 50 day moving average is $3.94 and its 200 day moving average is $3.89.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.